- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Nihar R. Desai, MD, MPH, vice chief of cardiology at the Yale School of Medicine, joined The American Journal of Managed Care® to talk about critical topics in managing cardiovascular disease. He highlighted the importance of patient education, shared decision-making, and addressing cost and access barriers. Desai also explored multiple innovative strategies such as behavioral economics, personalized medicine, and digital tools to improve adherence.
He explained that a holistic approach to care is needed, particularly in addressing racial and ethnic disparities and integrating personalized medicine to achieve health equity. Additionally, he spoke on the promise of new therapies and the role of remote care in enhancing patient outcomes and quality of life.
Listen above or on one of these podcast services:
Low Pulmonary Rehabilitation, Palliative Care Referrals for Patients With IPF Persist
October 30th 2024Despite proven benefits, referrals to pulmonary rehabilitation and palliative care for patients with idiopathic pulmonary fibrosis (IPF) in England remain significantly lower than for other respiratory conditions.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Zanubrutinib More Effective Than Ibrutinib in Treating Patients With Relapsed/Refractory CLL, SLL
October 30th 2024The long-term response rate for zanubrutinib was better than ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Read More
